VALPROATE USE IS ASSOCIATED WITH HIGHER MORTALITY AND HEPATIC DECOMPENSATIONIN PATIENTS WITH MASLD/ MASH: A MULTINATIONAL ANALYSIS

Authors

Donghyun Ko, Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, USA.
Do Han Kim MD, Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Wilhelm S. Basegoda MD, University of South Alabama, Mobile, AL, USA
Jose A. Porres, Universidad Francisco Marroquin, Guatemala City, Guatemala.
Luis M. Nieto MD, Division of Gastroenterology and Hepatology, Emory University, Atlanta, GA, USA.
Pedro Palacios Argueta MD, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
Paul T. Kroner MD, Department of Gastroenterology, Riverside Health System, Newport News, VA, USA.
Frank J. Lukens MD, Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL, USA

Document Type

Conference Proceeding

Abstract

Valproate is a widely used anti-seizure medication for treating epilepsy. However, it significantly impacts lipid metabolism by interfering with the beta-oxidation pathway of fatty acids in mitochondria. This disruption is expected to accelerate the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) in patients on chronic valproate therapy. The aim of this study is to determine whether the chronic use of valproate increases the risk of liver-related and cardiovascular events

Publication Date

5-2025

Recommended Citation

Ko, Donghyun; Kim, Do Han MD; Basegoda, Wilhelm S. MD; Porres, Jose A.; Nieto, Luis M. MD; Palacios Argueta, Pedro MD; Kroner, Paul T. MD; and Lukens, Frank J. MD, "VALPROATE USE IS ASSOCIATED WITH HIGHER MORTALITY AND HEPATIC DECOMPENSATIONIN PATIENTS WITH MASLD/ MASH: A MULTINATIONAL ANALYSIS" (2025). Posters. 105.
https://scholar.bridgeporthospital.org/poster_presentations/105